InjectionTirzepatide Injection
Tirzepatide
First-in-class dual GIP/GLP-1 receptor agonist (twincretin) demonstrating superior HbA1c reduction and up to 22.5% body weight loss in SURPASS and SURMOUNT trials, outperforming semaglutide across all dose levels in head-to-head studies. Available in six escalating weekly dose strengths as a single-dose auto-injector pen, supplied by Eli Lilly-aligned and Indian generic manufacturers for diabetes and obesity management globally.
Strengths
2.5mg / 5mg / 7.5mg / 10mg / 12.5mg / 15mg
Packing
1 pen/box
Origin
India (WHO-GMP)
MOQ
100 units
Export Price
On Request
Availability
In Stock
Product Specifications
Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.
Related Products
InjectionRetatrutide Injection
Retatrutide
Investigational triple incretin receptor agonist (GIP/GLP-1/Glucagon) demonstrating exceptional weight loss exceeding 24% body weight in Phase 2 trials, surpassing all currently approved anti-obesity medications and representing the next generation of metabolic therapies. Supplied by Indian manufacturers for research procurement and supplied to markets where investigational compounds are accessible under physician oversight.
TabletSemaglutide Tablets
Semaglutide
World's first oral GLP-1 receptor agonist (Rybelsus) utilizing SNAC absorption technology to enable gastrointestinal uptake of this large peptide molecule, providing once-daily tablet convenience for type 2 diabetes management with HbA1c reductions comparable to injectable GLP-1 agonists. Supplied in 30-tablet bottles from Novo Nordisk-aligned and Indian manufacturers and exported for diabetes management programs preferring non-injectable therapy.
InjectionSemaglutide Injection
Semaglutide
Long-acting GLP-1 receptor agonist with a 168-hour half-life enabling once-weekly subcutaneous dosing for type 2 diabetes (Ozempic, up to 2mg) and chronic weight management (Wegovy, 2.4mg), with proven cardiovascular risk reduction in the SUSTAIN and STEP trial programs. Available as a pre-filled pen from Novo Nordisk-aligned and Indian generic manufacturers and exported globally as one of the most prescribed GLP-1 agents for diabetes and obesity.
Need bulk pricing for Tirzepatide Injection?
Send us your quantity requirements and destination country for a custom quotation.
Get Bulk Quote